The estimated Net Worth of Global Health Innovation Fu... is at least $20.1 Milion dollars as of 21 June 2018. Global Fu owns over 166,666 units of ElectroCore Inc stock worth over $20,076,192 and over the last 6 years Global sold ECOR stock worth over $0.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Global Fu ECOR stock SEC Form 4 insiders trading
Global has made over 1 trades of the ElectroCore Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Global bought 166,666 units of ECOR stock worth $2,499,990 on 21 June 2018.
The largest trade Global's ever made was buying 166,666 units of ElectroCore Inc stock on 21 June 2018 worth over $2,499,990. On average, Global trades about 166,666 units every 0 days since 2018. As of 21 June 2018 Global still owns at least 3,346,032 units of ElectroCore Inc stock.
You can see the complete history of Global Fu stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Global Fu's mailing address?
Global's mailing address filed with the SEC is ONE MERCK DRIVE, , WHITEHOUSE STATION, NJ, 08889.
Insiders trading at ElectroCore Inc
Over the last 6 years, insiders at ElectroCore Inc have traded over $541,551 worth of ElectroCore Inc stock and bought 3,996,513 units worth $5,852,816 . The most active insiders traders include James L L Tullis, Joseph P Errico a Thomas J. Errico. On average, ElectroCore Inc executives and independent directors trade stock every 38 days with the average trade being worth of $422,718. The most recent stock trade was executed by Thomas J. Errico on 15 August 2024, trading 5,000 units of ECOR stock currently worth $30,600.
What does ElectroCore Inc do?
electrocore is, a us based electroceutical healthcare company, which is developing a range of non-invasive vagus nerve stimulation (nvns) patient administered therapies for the treatment of multiple conditions in neurology, psychiatry, gastroenterology and other fields. initial focus is on primary headache (migraine and cluster headache), with trials continuing in epilepsy, gastric motility disorders, depression and anxiety. electrocore, which was founded in 2005, has more than 30 employees and full time consultants with offices in the us (head office), germany (german and european head office), uk, italy, australia, and canada.
What does ElectroCore Inc's logo look like?
Complete history of Global Fu stock trades at ElectroCore Inc
ElectroCore Inc executives and stock owners
ElectroCore Inc executives and other stock owners filed with the SEC include:
-
Daniel Goldberger,
Chief Executive Officer, Director -
Joseph Errico,
Director -
Brian Posner,
Chief Financial Officer -
Daniel S. Goldberger,
CEO & Director -
Brian M. Posner,
CFO & Corp. Sec. -
Joseph P. Errico,
Co-Founder, Principal Investor & Director -
Hans Vitzthum,
Investor Relations -
Thomas Patton,
Independent Director -
Stephen Ondra,
Independent Director -
Trevor Moody,
Independent Director -
John Gandolfo,
Independent Director -
Thomas Errico,
Independent Director -
Peter Cuneo,
Independent Director -
Sylvester Steele,
Vice President, General Manager of the Government Channels Business Unit -
Eric Liebler,
Senior Vice President - Neurology -
Mike Romaniw,
Executive Vice President - Systems & Operations -
Michael Atieh,
Independent Chairman of the Board -
Dr. Peter S. Staats M.B.A., M.D.,
Chief Medical Officer -
Eric J. Liebler,
Sr. VP of Neurology -
Dr. Peter S. Staats,
Chief Medical Officer -
Carrie Kochek,
Sr. Director of HR -
Iain Strickland Ph.D.,
VP of Global Sales & Strategy -
Jackie Dorsky,
VP of Marketing -
Michael Romaniw,
Exec. VP of Systems & Operations -
Julie Ann Goldstein,
Director -
James L L Tullis,
Director -
Nicholas Colucci,
Director -
Global Health Innovation Fu...,
10% owner -
Carrie Smith Cox,
Director -
Ventures Ii, Llc Core,
10% owner -
Francis R. Amato,
Chief Executive Officer -
Peter S. Staats,
Chief Medical Officer -
Glenn S. Vraniak,
Chief Financial Officer -
Charles Steve Theofilos,
-
Patricia Wilber,
Director